Skip to content Skip to footer
Subscribe Now
TOP 20

Top 20 Radiopharmaceutical Companies of 2026

Shots:  The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.  Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
17 hours ago

Read more

VIEWPOINTS

A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001

Shots:   GH001, an inhaled formulation of mebufotenin, is emerging as a highly differentiated therapy for treatment-resistant depression, delivering ultra-rapid and profound symptom improvement – patients come to the clinic depressed and many leave in remission already on the same day. Long term, in a Phase 2b trial, 73% of patients who completed six months were in remission—substantially higher than the…
5 days ago

Read more

VIEWPOINTS

Powering the Next Era of Animal Health: Gary Yang on CPBIO’s Global Strategy 

Shots:  CPBIO’s expanding global footprint is powered by a science-led strategy that connects innovation, partnerships, and emerging market growth with a core goal: turning evidence-based R&D into practical solutions that improve livestock productivity, resilience, and sustainability.  The company delivers species-specific solutions across poultry, swine, ruminants, and aquaculture while following a unified R&D philosophy focused on…
February 16, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in January 2026 

Shots:  Approval numbers were lower, but the impact remained strong the FDA cleared one new drug in January 2026 versus three in January 2025, reflecting continued innovation in areas of high unmet need  Zycubo from Sentynl Therapeutics was approved for pediatric Menkes disease, offering a targeted treatment for this rare, life-threatening genetic copper deficiency disorder  Clinical results were striking, showing…
February 10, 2026

Read more

INSIGHTS+

Key Biosimilars Events of January 2026   

Shots:  Global biosimilar activity accelerated across ophthalmology, oncology, immunology, and diabetes, with new or advancing alternatives to Lucentis, Eylea, Stelara, Lantus, Avastin, Opdivo, and Neulasta, expanding patient access across Europe, the US, India, Canada, Ghana, and MENA  Regulatory and commercialization momentum remained strong, marked by FDA, EC, Health Canada, and Ghana FDA milestones, alongside Samsung Bioepis’…
February 3, 2026

Read more

PUBLICATIONS

A Quantitative Study on Awareness, Enrolment and Utilisation of Ayushman Bharat – PMJAY Scheme in a Rural Setting Under Pune District, Maharashtra 

Abstract  Background  India continues to face persistent challenges in ensuring affordable and equitable healthcare, particularly in rural areas, where out-of-pocket expenditures remain high. The Indian Government’s Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (PMJAY) is a flagship initiative toward achieving Universal Health Coverage (UHC), aiming to provide financial protection through cashless secondary and tertiary care. However, awareness, enrolment, and utilisation…
January 30, 2026

Read more

INSIGHTS+

EMA Marketing Authorization of New Drugs in December 2025   

Shots:  Innovation in drug development continues to reshape patient care across dermatology, cardiology, immunology, oncology, respiratory medicine, and infectious diseases, as regulatory momentum in Europe remains strong toward the end of 2025. Recent EMA actions highlight how advanced biologics, precision small molecules, and next-generation vaccines are translating clinical breakthroughs into real-world impact.  In December 2025, the EMA…
January 20, 2026

Read more

EVENTS

Get Tailored Highlights from the 44th Annual J.P. Morgan Healthcare Conference

Shots: The 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026 in San Francisco, California, stands as the most influential healthcare investment event on the global calendar. Widely recognized as the industry’s premier forum, the conference brings together global biopharma leaders, high-growth innovators, cutting-edge technology companies, and the investment community shaping the future…
December 30, 2025

Read more

EVENTS

Evolution Summit By Marcus Evans | 20-21 January 2026 | Four Seasons Hotel | Westlake Village, CA, USA

The Evolution Summit is an invitation-only, premium Summit bringing leading clinical trial executives and innovative suppliers and solution providers together. The Summit’s content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. This is an exclusive, invitation-only event. To learn more…
December 24, 2025

Read more

EVENTS

PharmaMarketing Summit By Marcus Evans | 22-23 January 2026 | Four Seasons Hotel | Westlake Village, CA, USA

The PharmaMarketing Summit is an invitation-only, premium Summit bringing leading pharmaceutical marketing executives and innovative suppliers and service providers together. The Summit’s content is aligned with key pharmamarketing challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. This is an exclusive, invitation-only event. To learn more or…
December 24, 2025

Read more

Load more